Nodal Marginal Zone Lymphoma · line 1 · Sofosbuvir/Velpatasvir 12 weeks
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-DAA-SOF-VEL |
| ID | IND-NMZL-1L-HCV-POSITIVE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NODAL-MZL |
| Sources | SRC-ARCAINI-2014 SRC-EASL-HCV-2023 SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — extends NMZL coverage to HCV-positive subset by mirroring SMZL HCV+ / HCV-MZL extranodal logic. Smaller evidence base than HCV-MZL extranodal; clinical co-lead sign-off pending. Open question for hematologist consult: should DAA-first be routed even in GELF-positive HCV+ NMZL, or should BR be added concurrently?
Used By
Algorithms
ALGO-NMZL-1L- ALGO-NMZL-1L